Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab or placebo with SBRT, and osimertinib after SBRT, for early-stage EGFR-defined or unselected NSCLC
NL-OMON60456Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + standard SBRT, Placebo + standard SBRT and Osimertinib after standard SBRT (3 arms). Primary endpoints: Progression-free survival in subset of T1 to T3N0M0 NSCLC by BICR and 4-year progression-free survival by ICR using RECIST 1.1. Started Oct 2019; status: active, not recruiting.
02
Drugs
durvalumabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60456.